Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03732010 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-03732010 | EXPERIMENTAL | Single Arm study |
| Name | Type | Description |
|---|---|---|
| PF-03732010 | DRUG | IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops. |
Inclusion Criteria: * Advanced solid tumors refractory to (or intolerant of) established therapy known to provide clinical benefit, or for which there is no standard therapy * Age \>= 18 years of age * Adequate bone marrow function as defined by: absolute neutrophil count (ANC) ≥1500/uL, hemoglobin...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
PF-03732010 is an investigational small molecule developed by Pfizer, Inc. for the treatment of advanced solid tumors and other neoplasms. It was studied in a single Phase 1 clinical trial in patients with advanced solid tumors. It is an experimental agent and is not an approved medicine.
PF-03732010 targets CDH3, also known as P-cadherin, and acts as an inhibitor of this target. CDH3 is a cell adhesion protein that is overexpressed in several tumor types, which made it an attractive target for an anti-cancer therapy. The compound was designed to inhibit CDH3 activity in tumor cells.
PF-03732010 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound in patients with advanced solid tumors. The drug remains an investigational Pfizer oncology asset.
PF-03732010 is in Phase 1 development. It has completed one Phase 1 clinical trial in patients with advanced solid tumors, and no later-stage trials have been conducted. The compound is investigational and has not been approved by the FDA or any other regulatory agency for any indication.
PF-03732010 was evaluated in one Phase 1 trial, NCT00557505, titled A Study Of PF-03732010 In Patients With Advanced Solid Tumors. That trial is completed and enrolled 43 patients across the United States, Australia, and South Korea. It was an uncontrolled study without randomization or blinding.
PF-03732010 was studied for the treatment of advanced solid tumors, which fall under the broader category of neoplasms. The Phase 1 trial enrolled 43 adult patients of any sex with advanced solid tumors. Because the compound is investigational, it is not currently used as a marketed treatment for neoplasms.